OptumRx, a UnitedHealth subsidiary, is tracking three new drugs this year:
- Brensocatib: An oral treatment for noncystic fibrosis bronchiectasis which gained FDA approval Aug. 12. It is the first targeted therapy for the chronic lung condition and has shown reduced exacerbations in clinical trials.
- Tolebrutinib: An oral therapy under FDA review for nonrelapsing secondary progressive multiple sclerosis — which impacts about 15% of patients and has limited treatment options. Tolebrutinib is the first drug to significantly slow disability progression in the population.
- Leqembi SC (lecanemab): A subcutaneous version of Alzheimer’s drug Leqembi pending FDA approval. If approved, it would be the first self-administered treatment in its class.
